PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Brentuximab vedotin→

Brentuximab Vedotin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
914088-09-8
FDA UNII
7XL5ISS668
PubChem Substance Record
SID 481101546
Approximate molecular weight
Approximately 153 kDa
Drug class
CD30-directed antibody–drug conjugate (brentuximab vedotin)
Mechanism of action
Brentuximab vedotin binds CD30 on target cells and is internalised. Lysosomal proteolysis releases monomethyl auristatin E (MMAE), which binds tubulin, disrupts microtubules, induces cell-cycle arrest and promotes apoptosis.
Indications / reported uses
  • EMA-authorised indications include selected CD30-positive Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and cutaneous T-cell lymphoma settings; consult current product information for exact lines and combinations

Sources: EMA EPAR — Adcetris · EMA product information · NCI Drug Dictionary

Identification sources: The FDA ADCETRIS prescribing information reports an approximate molecular weight of 153 kDa and approximately four MMAE molecules per antibody. Because the drug-to-antibody ratio varies, the conjugate has no single exact molecular formula or molecular weight.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Brentuximab Vedotin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brentuximab Vedotin Permitted Daily Exposure (PDE) report (the Brentuximab Vedotin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brentuximab Vedotin Occupational Exposure Limit (OEL) report (the Brentuximab Vedotin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.